Press Release

NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics

Posted 10.9.2017

NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics

San Diego, CA, October 9, 2017: Amydis Diagnostics, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases, announced today that they received a Phase 1 SBIR grant award from the National Institute on Aging of the National Institutes of Health (NIH). The grant award for more than $530,000 will fund research and development efforts for novel ophthalmic diagnostic probes for Cerebral Amyloid Angiopathy (CAA), an age-associated disease in which proteins called amyloid build up on the walls of the arteries in the brain increasing the risk for stroke caused by bleeding, and dementia.

“We are honored to have been selected for this highly competitive grant from NIH, our third award in the past three years. It will allow us to accelerate the development of our innovative chemistry and expand into another disease that involves the presence of amyloid proteins”, stated Stella Sarraf, Ph.D., Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “We believe that the eye represents a window to the brain and can be used as a proxy for diagnosing certain neurological diseases. To our knowledge, we are the first company to explore the possibility of detecting amyloid proteins in the retina associated with CAA.”

CAA is a major cause of spontaneous intracerebral hemorrhage in people older than 55 and an important contributor to age-related cognitive decline. Physicians are unable to diagnosis CAA with certainty without a sample of brain tissue. Current diagnosis of CAA involves expensive imaging tests such as MRI, CT scans, and PET amyloid tests. The development of a non-invasive ophthalmic amyloid test would be of value to physicians. “A retinal test for CAA will enable physicians to take better care of patients by avoiding medications contraindicated in this disease, thereby decreasing their likelihood of having a hemorrhagic stroke,” said Scott Reines, MD PhD, Chief Medical Officer of Amydis. “Such a test would also be extremely useful as an outcome marker in clinical trials focused on therapies for CAA that could stop or reverse progression of the disease by preventing vascular amyloid deposition.”

Disclosure

Research reported in this grant publication is supported by the National Institute On Aging of the National Institutes of Health under Award Number R43AG058350. The content is solely the responsibility of the Company and Principal Investigators and does not necessarily represent the official views of the National Institutes of Health.

About Amydis Diagnostics

Amydis Diagnostics, Inc., founded in 2013, is an early stage, privately-held pharmaceutical company focused on its platform of innovative chemistry to detect diseases that involve the presence of amyloid proteins. Amydis has a platform of novel compounds that fluoresces when bound to amyloid proteins, thus enabling non-invasive diagnosis of such diseases. The Company’s most advanced program is targeting the detection of early stage Alzheimer’s disease, a well-known amyloid disease. Other potential development programs include the detection of Cerebral Amyloid Angiopathy, Parkinson’s disease, Creutzfeldt-Jakob disease (mad cow disease), Pre-eclampsia, and TTR Amyloidosis, all of which are associated with the presence of amyloid proteins. For more information on Amydis, please visit www.amydis.com.

Contact

David H. Crean, Ph.D.
Chief Business Officer
david@amydis.com
858-245-4905





Press Release

Amydis Diagnostics Named to San Diego Venture Group’s (SDVG)
2017 Cool Companies List


 
SDVenture

Posted 5.30.2017

San Diego, CA, May 30, 2017: Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related disorders such as Alzheimer’s disease, today announced it has been named to the San Diego Venture Group’s (SDVG) 2017 Cool Companies list. The award honors the San Diego region’s leading technology companies for outstanding performance and for providing leading-edge products and services that fuel growth.

“We are honored to be selected as one of San Diego’s ‘coolest’ companies from so many strong contenders,” said Stella Sarraf, Ph.D., Interim Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “We are proud of our early success and innovation within the diagnostics and dementia space and pleased to represent the very best of the thriving San Diego life science industry.

Amydis was selected for providing game-changing technology that addresses an important problem today regarding the clinical need for diagnostic testing of Alzheimer’s disease in its early stages. The translational potential of the Company's innovative approach using a topical non-invasive ophthalmic diagnostic may help in identifying patients at risk for Alzheimer’s disease and provides a companion diagnostic for disease modifying treatments that may guide therapeutic intervention.

The complete list of San Diego Venture Group’s 2017 Cool Companies is available at https://www.sdvg.org/2017-sdvg-cool-companies-announced/. The 36 regionally based winning businesses will be prominently featured at the SDVG Venture Summit on June 15, which is expected to draw more than 300 attendees including Venture Capital firms from Silicon Valley and Los Angeles.

About San Diego Venture Group
The San Diego Venture Group is a non-profit business organization that fosters relationships and ideas to form, fund and build new ventures. SDVG is helping San Diego evolve into a significant entrepreneurial and venture center. Visit www.sdvg.org for more information.

About Amydis Diagnostics, Inc.
Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages, and in doing so, allows appropriate therapeutic options to be developed or pursued. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease. More information on Amydis can be found at www.amydis.com.

 

Amydis Diagnostics Contact

David H. Crean, Ph.D.
Chief Business Officer
david@amydis.com
858-245-4905



Press Release

AMYDIS DIAGNOSTICS ADDS VETERAN DRUG DEVELOPMENT EXECUTIVE AND CHIEF MEDICAL OFFICER TO MANAGEMENT TEAM


Posted 5.16.2017

San Diego, CA, May 17, 2017: Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related disorders such as Alzheimer’s disease, announced the addition of Scott A. Reines, M.D., Ph.D. to their executive team.  Dr. Reines will serve as Chief Medical Officer and work alongside Dr. Richard D’Souza in driving the R&D platform through clinical trials.

“Amydis is fortunate to have Scott join our executive team.  Dr. Reines has a unique blend of experience in neurology and ophthalmology and developing innovative branded products that make him an ideal fit for the Company,” said Stella Sarraf, Ph.D., Interim Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “Dr. Reines will lead the clinical development of our lead program in Alzheimer’s as well as help build our pipeline”.

“I have had the pleasure of working with Scott when I was at Merck and am excited to be teamed up with him again,” said Franz Hefti, Ph.D., Board Member of Amydis.  “He is a fantastic addition to the Amydis team.”

Dr. Reines is a research physician with broad drug development experience leading to the approval of new drugs in five different therapeutic areas including neurology and ophthalmology. Prior to Amydis, he has served in leading roles at Johnson & Johnson and Merck, and currently chairs a Data Safety Monitoring Board. As Senior Vice President for CNS, Pain and Translational Medicine at J&J, Dr. Reines oversaw the development and approval of numerous drugs for the treatment of schizophrenia, Alzheimer’s, pain and migraine headache.  Prior to that, Dr. Reines served as Vice President, Clinical Research at Merck with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology.  While there, he oversaw the conduct on one of the first large, multicenter trials for the prevention of Alzheimer’s disease and led the development of leading brand drugs for nausea and vomiting, migraine, Parkinson’s and glaucoma.

Dr. Reines served for two years as co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and spent five years on the National Drug Abuse Advisory Council. He is currently Vice Chair of the Board of Directors of KidsPeace, a national children’s psychiatric and behavioral healthcare provider He holds a bachelor’s degree in chemistry from Cornell University, a doctoral degree in chemistry/molecular biology from Columbia University, and a medical degree from Albert Einstein College of Medicine. He is Board Certified in Psychiatry and Neurology.

 
About Amydis Diagnostics, Inc.

Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages, and in doing so, allows appropriate therapeutic options to be developed or pursued. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease. More information on Amydis can be found at www.amydis.com.

Disclosure

This news release contains "forward-looking statements" concerning the development and commercialization of Amydis’ pipeline products, the potential benefits and attributes of such products, and the Company's expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this news release. Actual results may vary. Amydis undertakes no obligation to update any forward-looking statements for any reason.

 

Amydis Diagnostics Contact

David H. Crean, Ph.D.
Chief Business Officer
david@amydis.com
858-245-4905

Press Release

Press Release: Amydis Diagnostics Awarded NIA-NIH Grant


Posted 3.17.2017

Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease

San Diego, CA, March 19, 2017: Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related neurodegenerative disorders such as Alzheimer’s disease, announced that they received a Phase 2 SBIR grant award by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). The grant award for $1.8 million will fund research and development of a novel ophthalmic diagnostic probe for Alzheimer’s Disease. The company previously was awarded a Phase 1 grant from 2015-2016.  
Alzheimer’s disease is a significant healthcare burden and unmet medical need. Buildup and deposition of amyloid-beta plaques in the brain is a hallmark of the disease, and this accumulation continues to be the leading biomarker of interest for early detection. Accrual of amyloid-beta is believed to typically occur well before the appearance of clinical symptoms of cognitive decline.
The ability to identify amyloid-beta deposits helps in identifying patients at risk for Alzheimer’s disease and enables enrollment of patients in clinical trials investigating disease modifying treatments, and may ultimately guide therapeutic intervention at an early stage. Current diagnostic procedures to detect amyloid-beta in the brain are based on brain imaging techniques or biochemical assays following an invasive procedure. Amydis aims at establishing less costly, non-invasive diagnostic procedures based on ophthalmologic procedures.
“Amydis is fortunate to have been selected for this highly competitive grant award.  The award reflects NIA's commitment to finding truly novel approaches to detecting and treating Alzheimer's disease,” said Stella Sarraf, Ph.D., Interim Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “This grant provides rigorous peer-reviewed validation of the opportunity approach we've taken to the development of our technology and allows us to further develop and take our promising technology to the marketplace for the detection of amyloid-beta deposits as a diagnostic for Alzheimer’s disease".

.

About Amydis Diagnostics

Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease. More information on Amydis can be found at www.amydis.com.

Press Release: Amydis Diagnostics Awarded NIA-NIH Grant


Posted 9.29.2015

Amydis Diagnostics Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer’s disease

San Diego, CA, September 29, 2015: Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloidgenic protein-associated diseases, today announced a grant award by the National Institute of Aging (NIA), a center of the National Institute of Health (NIH). The grant award will fund research and development of a novel family of fluorescent probes to be used as diagnostic agents to image neurodegenerative diseases through an innovative ophthalmic approach.

According to the World Alzheimer 2015 reports, there is estimated to be 46.8 million people with dementia worldwide. There will be an estimated 9.9 million new cases of dementia in 2015, equivalent to one every 3.2 seconds. Alzheimer’s disease (AD) is a degenerative brain disease and the most common cause of dementia. It accounts for an estimated 60 percent to 80 percent of dementia cases.

“The company is extremely pleased to receive this grant award. It will allow Amydis to further develop our technology and bring a promising opportunity to the marketplace for the detection of AD”, said Stella Sarraf, Ph.D., Chief Executive Officer of Amydis Diagnostics, Inc.

Currently, diagnosis of amyloid-associated dementias in individuals showing symptoms of cognitive ne is extremely difficult, requiring multiple modes of testing over months to years. Early, pre-symptomatic diagnosis is even more challenging, if not impossible, with currently available technology. A simple and reliable method to identify the protein makeup of amyloid deposits in living patients could significantly aid in disease diagnosis, allowing the opportunity for disease-modifying therapeutic intervention. Through this award, Amydis aims to develop much needed diagnostic agents through an innovative approach utilizing standard technology available in eye care specialist offices.

About Amydis Diagnostics

Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease. More information on Amydis can be found at www.amydis.com.